<p>50 µg of purified antibody was intraperitoneally injected into Swiss mice (n = 3 or 4). Mice were sacrificed at different times to calculate plasma concentrations of mAb (• mTA12; cTA12) using a competitive immunoassay. Data were analysed and fitted with WinNonLin professional software (Pharsight®).</p
<p>A. Concentration of ALT (U/L) in serum of the mice shown as Mean ± SD. B. Concentration of AST (U...
<p>Concentration of AMD070 in the lungs of CD-1 mice at various times after PO administration at 400...
<p>(<b>A</b>) muPCSK9 levels in plasma samples from pre-immunized (W0) and post-immunized mice (W8)....
<p>Purified antibody (50 µg) was injected intraperitoneally into Swiss mice (n = 4). Mice were sacri...
Safety and pharmacokinetic analysis of immunotherapeutic Mabs (A) Survival of Caco2 cell after co-cu...
<p>The same amount of human IgGs (500 µg) as used in the challenge studies were administered via i.p...
<p>Mice (n = 3/group) received a single IV injection of MTM-SK (A) or MTM-SDK (B) and plasma levels ...
Pharmacokinetic evaluation of peripheral and brain antibody level following intravenous injection of...
<p>The neutralizing activity was determined using the mouse protection assay with 5 estimated MLD<su...
1. The in vivo pharmacokinetics (PK) profiles of a novel c-Met antibody–drug conjugate (ADC), SHR-A1...
<p>A. BIA mice; B. CIA mice; C. BIA-CIA mice. For protein extraction and antibody hybridization, who...
<p>The concentrations of anti-TcpA (A) and anti-CTB (B) antibodies were measured by quantitative ELI...
<p>The % value was calculated with the formula [100×(concentration of each day/concentration of the ...
<p>Plasma was collected over a period of 15 minutes—48 hours after M10 injection and measured by ind...
<p>Immunogenicity of VLP-VP2 in mice (determination of antibody titers of VLP-VP2 in mice).</p
<p>A. Concentration of ALT (U/L) in serum of the mice shown as Mean ± SD. B. Concentration of AST (U...
<p>Concentration of AMD070 in the lungs of CD-1 mice at various times after PO administration at 400...
<p>(<b>A</b>) muPCSK9 levels in plasma samples from pre-immunized (W0) and post-immunized mice (W8)....
<p>Purified antibody (50 µg) was injected intraperitoneally into Swiss mice (n = 4). Mice were sacri...
Safety and pharmacokinetic analysis of immunotherapeutic Mabs (A) Survival of Caco2 cell after co-cu...
<p>The same amount of human IgGs (500 µg) as used in the challenge studies were administered via i.p...
<p>Mice (n = 3/group) received a single IV injection of MTM-SK (A) or MTM-SDK (B) and plasma levels ...
Pharmacokinetic evaluation of peripheral and brain antibody level following intravenous injection of...
<p>The neutralizing activity was determined using the mouse protection assay with 5 estimated MLD<su...
1. The in vivo pharmacokinetics (PK) profiles of a novel c-Met antibody–drug conjugate (ADC), SHR-A1...
<p>A. BIA mice; B. CIA mice; C. BIA-CIA mice. For protein extraction and antibody hybridization, who...
<p>The concentrations of anti-TcpA (A) and anti-CTB (B) antibodies were measured by quantitative ELI...
<p>The % value was calculated with the formula [100×(concentration of each day/concentration of the ...
<p>Plasma was collected over a period of 15 minutes—48 hours after M10 injection and measured by ind...
<p>Immunogenicity of VLP-VP2 in mice (determination of antibody titers of VLP-VP2 in mice).</p
<p>A. Concentration of ALT (U/L) in serum of the mice shown as Mean ± SD. B. Concentration of AST (U...
<p>Concentration of AMD070 in the lungs of CD-1 mice at various times after PO administration at 400...
<p>(<b>A</b>) muPCSK9 levels in plasma samples from pre-immunized (W0) and post-immunized mice (W8)....